December 2016
-
Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled “Dry Powder… Read more . . .
-
Finnish nanonization specialist Nanoform has announced the appointments of Eric Peter and Sergie Letser to the company’s US business development team. In January 2020, Nanoform announced the appointment of Sally Langa as its new Head of… Read more . . .
-
MediciNova said that it has tested a number of intranasal SARS-CoV-2 vaccine prototypes using a viral vector technology platform from Mie University and BioComo and has identified several candidates that it plans to advance. BioComo’s… Read more . . .
-
H&T Presspart and Hovione Technology have revealed their collaboration with Bilim Pharmaceuticals on a dry powder inhaler based on the PowdAir Plus device. H&T Presspart acquired global rights to the capsule based DPI device from Hovione… Read more . . .
-
Inhaled drug company MannKind Corporation has announced the appointment of Kevin Kaiserman as VP, Medical Affairs and Safety. Kaiserman, a pedicatric endocrinologist, was most recently in private practice. The company markets Afrezza inhaled insulin, which was… Read more . . .
-
Esketamine (Spravato) and sumatriptan (Tosymra) nasal sprays are among the latest set of product specific draft guidances published by the FDA. Earlier this year, the agency published a product specific guidance for sumatriptan nasal powder.… Read more . . .
-
Partner Therapeutics (PTx) has announced the initiation of the iLeukPulm Phase 2 trial of an inhaled formulation of its Leukine sargramostim in hospitalized COVID-19 patients in respiratory distress. Partner recently signed a $35 million contract… Read more . . .
-
Altimmune has announced that a preclinical study of its intranasal COVID-19 vaccine candidate AdCOVID has demonstrated a strong immune response in the lungs of mice, particularly in the stimulation of CD8+ T cells. In July… Read more . . .
-
Union Therapeutics said that a Phase 1 SAD/MAD trial of UNI911 dry powder niclosamide in 44 healthy volunteers was completed successfully, confirming the safety of the inhaled formulation. The company recently acquired an option for… Read more . . .
-
Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics’ MMS019 nasal powder, which it calls a “high density molecular masking spray” and which is intended to block viruses from taking hold in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland